RxDoctor Payments Data

Michael Deyoung, DO

Cardiovascular Disease · Mount Clemens, MINPI 1487861043

Payments from drug & device makers

$77,195in general payments, 2019–2025

Across 447 payments — averaging $172.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$38K
  • Cardiovascular Systems Inc.$12K
  • Medtronic$9K
  • AstraZeneca$8K
  • Boston Scientific$2K
  • Abiomed$2K
  • plus $6K from 34 others

What the payments were for

  • Consulting fees$10,75016%
  • Speaking & faculty fees$33,02048%
  • Travel & lodging$12,59818%
  • Food & beverage$12,64418%
  • Education$2000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$77,195 in reported general payments places this provider in the 85th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$188,715
Medicare patients
573
Services billed
2,164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban392$494,949
XareltoRivaroxaban103$153,923
EntrestoSacubitril/Valsartan73$115,089
FarxigaDapagliflozin Propanediol45$53,744
Repatha SureclickEvolocumab37$40,435
BrilintaTicagrelor38$37,080
JardianceEmpagliflozin26$31,269
Praluent PenAlirocumab20$16,271
Ranolazine ErRanolazine37$6,944
Atorvastatin Calcium390$6,801
ClopidogrelClopidogrel Bisulfate301$6,649
Metoprolol Succinate324$5,820
Carvedilol276$4,313
Losartan Potassium245$3,504
Propafenone Hcl29$3,499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$255$494,949392 claims
Johnson & JohnsonXarelto$367$153,923103 claims
NovartisEntresto$694$115,08973 claims
AstraZenecaFarxiga, Brilinta$8,164$90,82483 claims
Boehringer IngelheimJardiance$118$31,26926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Mount Clemens

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →